News from ucb A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Dec 02, 2023, 07:00 ET UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting

Study presents new persistence analysis of FINTEPLA, evaluating the efficacy and tolerability of FINTEPLA over a span of 12 months1 Real-world data...

Dec 01, 2023, 07:00 ET UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting

UCB will present 29 abstracts, including 4 late breakers, at American Epilepsy Society Annual Meeting 2023 highlighting clinical, health economic and ...

Nov 14, 2023, 07:00 ET UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

UCB, a global biopharmaceutical company, announced today that BIMZELX® (bimekizumab-bkzx) is commercially available for the treatment of...

Nov 11, 2023, 07:00 ET Post Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF)

A post hoc analysis from the EXXELERATE Phase 4 trial showed that 65.7 percent of CIMZIA-treated patients with rheumatoid arthritis (RA) and high...

Nov 10, 2023, 07:00 ET UCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023

UCB, a global biopharmaceutical company, today announced new long-term data from the BIMZELX® (bimekizumab) Phase 2b study BE AGILE and its...

Nov 01, 2023, 07:00 ET UCB presents latest data from generalized myasthenia gravis portfolio at 2023 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session

14 presentations – including 3 oral sessions – have been selected by AANEM and MGFA for inclusion across scientific programs Results presented across ...

Oct 31, 2023, 07:00 ET NAYZILAM® (midazolam) Results Published in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

Median time to return to full baseline function occurred within 90 minutes following outpatient treatment with NAYZILAM® (midazolam) nasal spray,...

Oct 18, 2023, 07:00 ET BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

Regulated Information – Inside Information – UCB, a global biopharmaceutical company, announced today that the U.S. Food and Drug Administration...

Oct 17, 2023, 18:34 ET UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis

FDA approval of ZILBRYSQ® (zilucoplan) has been granted for the treatment of generalized myasthenia gravis (gMG) in adult patients who are...

Oct 13, 2023, 12:00 ET UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB, a global biopharmaceutical company, today announced that it will present six abstracts in hidradenitis suppurativa (HS) at the 8th Annual...

Oct 12, 2023, 12:20 ET Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

UCB, a global biopharmaceutical company, today announced the first analyses of pooled data from the two Phase 3 bimekizumab studies (BE HEARD I and...

Oct 04, 2023, 13:06 ET UCB presents late-breaking posters at Child Neurology Society Meeting

The Child Neurology Society Meeting, a prominent event in the field of pediatric neurology, is set to showcase cutting-edge research and developments ...

Jul 21, 2023, 07:00 ET UCB announces U.S. availability of RYSTIGGO® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.

RYSTIGGO is now commercially available by prescription in the United States for adult patients with gMG who are anti-acetylcholine receptor (AChR) or ...

Jun 27, 2023, 07:00 ET UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis

FDA approval of RYSTIGGO® (rozanolixizumab-noli) has been granted under the Priority Review designation for the treatment of generalized myasthenia...

Apr 20, 2023, 07:00 ET UCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual Meeting

UCB will showcase data from its expansive and innovative neurology portfolio at the 75th American Academy of Neurology (AAN) Annual Meeting, April...

Apr 17, 2023, 07:14 ET UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance

UCB (Euronext: UCB), a global biopharmaceutical company, today announced the U.S. Drug Enforcement Administration (DEA) has published a final rule...

Mar 18, 2023, 14:10 ET Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks

Patients treated with investigational bimekizumab, an IL-17A and IL-17F inhibitor, achieved statistically significant and clinically meaningful...

Mar 16, 2023, 07:00 ET UCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis, and Hidradenitis Suppurativa

UCB, a global biopharmaceutical company, today announced that it will present eight bimekizumab abstracts across a range of IL-17 mediated...

Jan 18, 2023, 07:00 ET Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB, a global biopharmaceutical company, today announced that Annals of the Rheumatic Diseases has published 24-week results from the Phase 3 BE...

Jan 06, 2023, 07:00 ET UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

Biologic License Application (BLA) designated Priority Review by FDA and seeks approval for rozanolixizumab for the treatment of adults with...

Dec 09, 2022, 07:00 ET UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

Top-line results show that the two Phase 3 studies, BE HEARD I and BE HEARD II, met their primary and key secondary endpoints with statistical...

Dec 07, 2022, 07:00 ET The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

UCB, a global biopharmaceutical company, today announced that The Lancet has published two articles detailing 24-week results from the Phase 3 BE...

Dec 01, 2022, 07:00 ET UCB to present data at the American Epilepsy Society 76th Annual Meeting 2022 supporting a decades-long commitment to transforming epilepsy care

21 scientific presentations, including 7 late breakers, showcase the breadth of UCB's portfolio, reinforcing commitment to improving the lives of...

Nov 23, 2022, 07:00 ET Epilepsia Publishes Interim Results of Open-Label Extension Study of FINTEPLA® (fenfluramine) Oral Solution in Patients with Lennox-Gastaut Syndrome (LGS)

Peer-reviewed results from the Phase 3 open-label extension study of FINTEPLA® in LGS provide significant reduction in the frequency of multiple...

Dec 10, 2021, 07:00 ET UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis

UCB, a global biopharmaceutical company, today announced positive topline results from the Phase 3 MycarinG study1 evaluating rozanolixizumab, a...